Report Library
All ReportsNon-Alcoholic Steatohepatitis (NASH) Survey
January 04, 2017
We conducted a 4-question survey of 42 United States and 40 European (based in France, Germany, Italy and United Kingdom)
gastroenterologists to gauge their views on late-stage clinical candidates in non-alcoholic steatohepatitis (NASH), including Ocaliva (ICPT),
elafibranor (GNFTF) and selonsertib (GILD), and their projected use of these drugs if FDA-approved.
If you are a KOL Insight Subscriber, please access the survey from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
If you are a KOL Insight Subscriber, please access the survey from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Non-Alcoholic Steatohepatitis (NASH) |